Navigation Links
Effective prostate cancer treatment discovery

Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers the most common cancer in Australian men.

For more than 60 years the main way to treat men with prostate cancer has involved removing the hormones that fuel growth of the cancer cells. Although initially effective this treatment inevitably fails and when the tumour growth resumes, the disease in incurable. The team, from the Prostate & Breast Cancer Research Program, has discovered a way to treat these potentially fatal diseased cells, which remain in a patient after they have undergone hormone treatment.

The findings have been published in the prestigious medical journal PNAS.

Associate Dean, Research Centres & Institutes and co-author Professor Gail Risbridger said the studies provided proof of the controversial concept that estrogens (hormones mainly thought as being important for women) could be good for men and used therapeutically to treat prostate cancer.

"The research showed that drugs that activate one of the two estrogen receptors, causes cell death. Most commonly cell death in patients with prostate cancer is achieved by withdrawing androgens (male hormones) which results in castration," Professor Risbridger said.

"Although the bulk of the tumour is removed by castration, some cells remain and these castrate-resistant cells are the ones that give rise to recurrent incurable disease"

The team used a drug developed to selectively and specifically activate the beta estrogen receptor in the prostate.

"It not only inhibits the growth of prostate cancer but also kills off cancer cells that are resistant to conventional treatment such as androgen deprivation therapy, more commonly known as castration therapy and does so using a mechanism that is different to castration." Professor Risbridger said.

The team made the discovery in animal models, and then successfully replicated laboratory results using human cells and tissues from patients with prostate cancer.

"The team at Monash University has discovered how this compound working through the beta receptors targets a small, but very important, population of cells in the tumour. It is a significant piece of the puzzle that will help medical research in this field an achievement that could eventually enhance treatment options for patients around the world with advanced prostate cancer." Professor Risbridger said.

Prostate cancer is the most common cancer in Australian men and is the second most common cause of cancer deaths in men. Each year in Australia, close to 3,300 men die of prostate cancer - equal to the number of women who die from breast cancer annually. About 20,000 new cases are diagnosed in Australia every year and one in nine men will develop prostate cancer in their lifetime. Current treatments of prostate cancer include hormone therapy however patient side effects can be devastating.

"This research also has personal meaning and provides me with the imperative to conduct basic biomedical research where the fundamental outcomes such as those we describe, may ultimately translate into more effective ways to treat prostate cancer" Professor Risbridger said.


Contact: Samantha Blair
Monash University

Related medicine news :

1. Study Shows Sani-Bag+ to be an Effective Microbial Barrier
2. Mammogram Plus MRI Cost-Effective in High-Risk Women
3. Mammogram Plus MRI Seems Cost-Effective in High-Risk Women
4. Two Sepsis Treatments Look Equally Effective
5. New drug for kidney transplant recipients effective in humans
6. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
7. Charging less for more effective treatments could reduce health care costs while improving health
8. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
9. Neuroimaging study may pave way for effective Alzheimers treatments
10. Gastric Banding Most Effective for Obese Teens
11. Low forms of cyclin E reduce breast cancer drugs effectiveness
Post Your Comments:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
Breaking Medicine Technology: